RTSN Retension Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 2002988 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets47.1%
Debt / equity—
Current ratio2.12x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | — | — | — | — |
| R&D expense | $5.02M | — | — | $1.37M | — | — |
| SG&A expense | $990,759 | — | — | $299,574 | — | — |
| Operating income | -$6.01M | — | — | -$1.66M | — | — |
| Net income | -$5.92M | -$4.14M | -$3.38M | -$1.48M | -$1.23M | -$656,497 |
| EPS (basic) | -7.33 | — | — | -1.83 | — | — |
| EPS (diluted) | -7.33 | — | — | -1.83 | — | — |
| Weighted avg. shares (diluted) | 807,894 | — | — | 805,154 | — | — |
| Balance sheet | ||||||
| Cash & equivalents | $9.19M | — | — | $19.42M | — | — |
| Current assets | $14.15M | — | — | — | — | — |
| Total assets | $14.15M | — | — | — | — | — |
| Current liabilities | $6.66M | — | — | — | — | — |
| Total liabilities | $6.66M | — | — | — | — | — |
| Shareholders' equity | -$20.66M | -$14.92M | -$10.93M | -$4.99M | -$3.55M | -$2.35M |
| Shares outstanding | 807,928 | — | — | — | — | — |
| Cash flow statement | ||||||
| Operating cash flow | — | — | — | — | — | — |
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.